These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 10738999

  • 21. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
    Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Giebel S, Skotnicki AB, Piatkowska-Jakubas B, Kuliczkowski K, Kiełbiński M, Zawilska K, Kłoczko J, Wrzesień-Kuś A, Polish Adult Leukemia Group.
    Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
    [Abstract] [Full Text] [Related]

  • 22. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
    Giebel S, Krawczyk-Kulis M, Adamczyk-Cioch M, Jakubas B, Palynyczko G, Lewandowski K, Dmoszynska A, Skotnicki A, Nowak K, Holowiecki J, Polish Adult Leukemia Group.
    Ann Hematol; 2006 Oct; 85(10):717-22. PubMed ID: 16832677
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia.
    Kantarjian HM, Walters RL, Keating MJ, Estey EH, O'Brien S, Schachner J, McCredie KB, Freireich EJ.
    Cancer; 1990 Jan 01; 65(1):5-8. PubMed ID: 2293869
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients.
    Di Bona E, Pogliani E, Rossi G, Lerede T, D'Emilio A, Vespignani M, Rodeghiero F, Barbui T, Bassan R.
    Leuk Lymphoma; 2005 Jun 01; 46(6):879-84. PubMed ID: 16019533
    [Abstract] [Full Text] [Related]

  • 27. Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Ochs J, Rivera GK, Pollock BH, Buchanan G, Crist W, Freeman AI.
    Cancer; 1990 Oct 15; 66(8):1671-7. PubMed ID: 2208021
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng YM, Baier M, Plezia P.
    J Clin Oncol; 1993 Oct 15; 11(10):2002-9. PubMed ID: 8410125
    [Abstract] [Full Text] [Related]

  • 30. Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence.
    MacCallum PK, Davis CL, Rohatiner AZ, Lim J, Gupta RK, Whelan JS, Price CG, Evans ML, Amess JA, Leahy M.
    Leukemia; 1993 Oct 15; 7(10):1496-9. PubMed ID: 8412309
    [Abstract] [Full Text] [Related]

  • 31. Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.
    Liedtke M, Dunn T, Dinner S, Coutré SE, Berube C, Gotlib J, Patel S, Medeiros B.
    Leuk Res; 2014 Dec 15; 38(12):1441-5. PubMed ID: 25449689
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.
    Hatsumi N, Miyawaki S, Yamauchi T, Takeshita A, Komatsu N, Usui N, Arai Y, Ishida F, Morii T, Kano Y, Ogura M, Machida S, Nishii K, Honda S, Ohnishi K, Naoe T, Japan Adult Leukemia Study Group (JALSG).
    Int J Hematol; 2019 Apr 15; 109(4):418-425. PubMed ID: 30725360
    [Abstract] [Full Text] [Related]

  • 34. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
    Karp JE, Smith BD, Levis MJ, Gore SD, Greer J, Hattenburg C, Briel J, Jones RJ, Wright JJ, Colevas AD.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4467-73. PubMed ID: 17671131
    [Abstract] [Full Text] [Related]

  • 35. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
    Lockhart S, Plunkett W, Jeha S, Ramirez I, Zipf T, Cork A, Pinkel D.
    J Clin Oncol; 1994 Mar 01; 12(3):587-95. PubMed ID: 8120558
    [Abstract] [Full Text] [Related]

  • 36. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R, Lerede T, Buelli M, Borleri G, Bellavita P, Rambaldi A, Barbui T.
    Haematologica; 1998 May 01; 83(5):422-7. PubMed ID: 9658726
    [Abstract] [Full Text] [Related]

  • 37. Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia.
    Harousseau JL, Milpied N, Brière J, Desablens B, Ghandour C.
    Nouv Rev Fr Hematol (1978); 1990 May 01; 32(4):227-30. PubMed ID: 2290708
    [Abstract] [Full Text] [Related]

  • 38. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
    Wrzesień-Kuś A, Robak T, Wierzbowska A, Lech-Marańda E, Pluta A, Wawrzyniak E, Krawczyńska A, Kuliczkowski K, Mazur G, Kiebiński M, Dmoszyńska A, Wach M, Hellmann A, Baran W, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Polish Adult Leukemia Group.
    Ann Hematol; 2005 Sep 01; 84(9):557-64. PubMed ID: 15856358
    [Abstract] [Full Text] [Related]

  • 39. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, Dekker AW, Berneman ZN, Thyss A, van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R.
    J Clin Oncol; 1998 Mar 01; 16(3):872-81. PubMed ID: 9508168
    [Abstract] [Full Text] [Related]

  • 40. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.
    Brito-Babapulle F, Catovsky D, Slocombe G, Newland AC, Marcus RE, Goldman JM, Galton DA.
    Cancer Treat Rep; 1987 Feb 01; 71(2):161-3. PubMed ID: 3467843
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.